Community Practice Connections: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation

Community Practice Connections: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation is organized by Physicians' Education Resource LLC (PER) and will be held from Aug 15, 2018 - Aug 15, 2019.

The target audience for this medical event is medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of ovarian cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the management of patients with ovarian cancer are also invited to participate. This CME Conference has been approved for a maximum of 1.5 Credits.

Description:
The landscape of therapeutic options for patients with ovarian cancer continues to evolve at a rapid pace, including the approval of multiple PARP inhibitors for treatment and maintenance indications following the results of recent key studies. It can be difficult for any clinician to keep up with the accelerated pace and volume of clinical advancements associated with PARP inhibition, and we have created an educational activity to help you to stay current and arm yourselves with the clinical knowledge and insight necessary to optimize safety and efficacy outcomes for your patients.

This web-based activity, based upon content presented at an ancillary event to the 2018 ASCO Annual Meeting, will present the latest data on PARP inhibition and the clinical implications of the data for your practice. The format will feature video clips of leading clinical experts in the treatment of ovarian cancer, who will address key learning points pertaining to the use of PARP inhibition in ovarian cancer. Multiple topics will be explored, including strategies for optimizing application of PARP inhibitor therapy for your patients when appropriate, approaches to assist you with the mitigation of PARP inhibitor-associated adverse events, and considerations for potential future directions and applications for PARP inhibition.

Learning Objectives
At the conclusion of this activity, you should be better prepared to:
• Define safety and efficacy outcomes from clinical trials of PARP inhibitors, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy
• Identify strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with ovarian cancer
• Describe the therapeutic rationale for use of PARP inhibitors in combination with other novel treatments, including evaluating specific clinical trials using PARP inhibitors in combination and recognizing the potential for enrolling patients in these trials
• Utilize the most up-to-date clinical evidence on PARP inhibitors for clinical decision making in patients with ovarian cancer in the context of current evolving treatment options